Fluidigm Introduces High-Parameter Maxpar Mass Cytometry Panels for Immuno-Oncology Research
Nov 10, 2016 13:30 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2016 -- Fluidigm Corporation (NASDAQ:FLDM) today announced the introduction of a modular set of high-parameter Maxpar® mass cytometry panels for immuno-oncology research. Designed...
Nov 10, 2016 13:30 pm UTC| Business
HASBROUCK HEIGHTS, N.J., Nov. 10, 2016 -- Demand Gen Report will host its third annual Strategy Planning Series (#SPS16) — a week-long webinar series presenting expert advice on modern, targeted approaches to demand...
FuelCell Energy Announces a New Project with E.ON Connecting Energies
Nov 10, 2016 13:30 pm UTC| Business
Sale to E.ON Connecting Energies GmbH as part of collaborative joint business approach Utility ownership model for replicable on-site power applications in EuropeHighly efficient and easy to site combined heat and power...
Argos Therapeutics to Participate in SITC 2016 Annual Meeting
Nov 10, 2016 13:30 pm UTC| Business
DURHAM, N.C., Nov. 10, 2016 -- Argos Therapeutics Inc. (Nasdaq:ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis®...
VirTra Announces Application for Listing on OTCQX
Nov 10, 2016 13:30 pm UTC| Business
TEMPE, Ariz., Nov. 10, 2016 -- VirTra, Inc.(OTC Pink:VTSID), a leading provider of judgmental use of force simulators and firearms training simulators, announced todaythat it has submitted its application to uplist the...
Fibrocell Appoints Alfred T. Lane, MD, Chief Medical Advisor
Nov 10, 2016 13:30 pm UTC| Business
EXTON, Pa., Nov. 10, 2016 -- Fibrocell Science, Inc. (NASDAQ:FCSC) today announced the appointment of Alfred T. Lane, MD, as Chief Medical Advisor of Fibrocell. A board certified dermatologist and pediatrician, Dr. Lane...
Minerva Neurosciences to Present at Jefferies 2016 London Healthcare Conference on November 17, 2016
Nov 10, 2016 13:30 pm UTC| Business
WALTHAM, Mass., Nov. 10, 2016 -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today...